Agios Pharmaceuticals, Inc.
A biopharmaceutical company in Cambridge, Massachusetts, that develops treatments for rare blood disorders by targeting cellular metabolism. Its main product, PYRUKYND (mitapivat), is an oral medicine for hemolytic anemia in adults with pyruvate kinase deficiency. Founded in 2008 by three cancer researchers, the company takes its name from the Greek word for "holy" — and sold its cancer business in 2021 to focus on rare genetic diseases.
Granted 140.9K · Sold 137.5K
Granted 303.5K · Sold 145.6K
Granted 81.6K · Sold 34.4K
Granted 103.0K · Sold 49.3K
Granted 74.9K · Sold 26.1K
Granted 70.3K · Sold 46.0K
Granted 66.7K · Sold 23.7K
Granted 10.7K · Sold 2.4K
Granted 8.3K
Granted 32.9K · Sold 20.0K
Granted 12.9K
Granted 8.3K · Sold 6.0K
Granted 10.9K
Granted 8.9K
Granted 16.2K · Sold 5.9K
Granted 2.0K
Granted 23.9K · Sold 26.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schenkein David PDirector · 9 transactions | +0.7% | 476.1Kas of Jun 2024 | 140.9K | — | 137.5K |
| Goff BrianChief Executive Officer, Director · 34 transactions | +419.7% | 191.1K | 303.5K | — | 145.6K |
| Fouse Jacqualyn ADirector · 11 transactions | +44.1% | 154.2K | 81.6K | — | 34.4K |
| Gheuens SarahChief Medical Officer · 41 transactions | +232.3% | 80.3K | 103.0K | — | 49.3K |
| Jones CeciliaChief Financial Officer · 28 transactions | +1353.8% | 55.0K | 74.9K | — | 26.1K |
| Burns James WilliamChief Legal Officer · 32 transactions | +106.4% | 49.3K | 70.3K | — | 46.0K |
| Milanova TsvetaChief Commercial Officer · 20 transactions | +1122.4% | 46.8K | 66.7K | — | 23.7K |
| Scadden DavidDirector · 15 transactions | +68.8% | 20.4K | 10.7K | — | 2.4K |
| Ho MaykinDirector · 3 transactions | +72.2% | 19.8K | 8.3K | — | — |
| Ballal Rahul D.Director · 12 transactions | +561.6% | 15.2K | 32.9K | — | 20.0K |
| Smith CynthiaDirector · 5 transactions | +561.6% | 15.2K | 12.9K | — | — |
| Foster-Cheek Kaye IDirector · 7 transactions | -9% | 12.5K | 8.3K | — | 6.0K |
| Capello Jeffrey DDirector · 5 transactions | — | 10.9K | 10.9K | — | — |
| Owen Adams CatherineDirector · 4 transactions | — | 10.9K | 8.9K | — | — |
| Viswanadhan KrishnanChief Corp Dev & Strategy · 4 transactions | — | 10.3K | 16.2K | — | 5.9K |
| Owen Catherine E.Director · 1 transaction | — | 2.0Kas of Jun 2024 | 2.0K | — | — |
| Washburn Theodore James Jr.Principal Accounting Officer · 26 transactions | -68.3% | 868 | 23.9K | — | 26.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -523.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.